Hoang Harry, Mellal Amine, Dulloo Milad, Nguyen Ryan T, Al-Saidi Neil Nazar, Magableh Hamzah, Cailleteau Alexis, Ghaith Abdul Karim, El-Hajj Victor Gabriel, Elmi-Terander Adrian
Faculty of Medicine, Department of Clinical Neurosciences, University of Geneva, 1205 Geneva, Switzerland.
Department of Neurosurgery, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Brain Sci. 2024 Dec 4;14(12):1226. doi: 10.3390/brainsci14121226.
BACKGROUND/OBJECTIVES: Spinal astrocytomas (SA) represent 30-40% of all intramedullary spinal cord tumors (IMSCTs) and present significant clinical challenges due to their aggressive behavior and potential for recurrence. We aimed to pool the evidence on SA and investigate predictors of regrowth or recurrence after surgical resection.
A systematic review and meta-analysis were conducted on peer-reviewed human studies from several databases covering the field of SA. Data were collected including sex, age, tumor location, extent of resection, histopathological diagnosis, and adjuvant therapy to identify predictors of SA recurrence. Recurrence was defined as failure of local tumor control or regrowth after treatment.
A total of 53 studies with 1365 patients were included in the meta-analysis. A postoperative deterioration in neurological outcomes, as assessed by the modified McCormick scale, was noted in most of the patients. The overall recurrence rate amounted to 41%. On meta-analysis, high-grade WHO tumors were associated with higher odds of recurrence (OR = 2.65; 95% CI: 1.87, 3.76; = 0.001). Similarly, GTR was associated with lower odds of recurrence compared to STR (OR = 0.33; 95% CI: 0.18, 0.60; = 0.0003). Sex ( = 0.5848) and tumor location ( = 0.3693) did not show any significant differences in the odds of recurrence. Intraoperative neurophysiological monitoring was described in 8 studies and adjuvant radiotherapy in 41 studies.
The results highlight the significant importance of tumor grade and extent of resection in patient prognosis. The role of adjuvant radiotherapy remains unclear, with most studies suggesting no differences in outcomes, with limitations due to potential confounders.
背景/目的:脊髓星形细胞瘤(SA)占所有髓内脊髓肿瘤(IMSCT)的30%-40%,因其侵袭性和复发可能性而带来重大临床挑战。我们旨在汇总关于SA的证据,并研究手术切除后再生长或复发的预测因素。
对来自多个涵盖SA领域的数据库的同行评审人体研究进行系统评价和荟萃分析。收集的数据包括性别、年龄、肿瘤位置、切除范围、组织病理学诊断和辅助治疗,以确定SA复发的预测因素。复发定义为治疗后局部肿瘤控制失败或再生长。
荟萃分析共纳入53项研究中的1365例患者。大多数患者经改良麦考密克量表评估术后神经功能恶化。总体复发率为41%。荟萃分析显示,世界卫生组织高级别肿瘤复发几率更高(OR = 2.65;95%CI:1.87,3.76;P = 0.001)。同样,与次全切除(STR)相比,全切除(GTR)与较低的复发几率相关(OR = 0.33;95%CI:0.18,0.60;P = 0.0003)。性别(P = 0.5848)和肿瘤位置(P = 0.3693)在复发几率上未显示任何显著差异。8项研究描述了术中神经生理监测,41项研究描述了辅助放疗。
结果突出了肿瘤分级和切除范围对患者预后的重要意义。辅助放疗的作用仍不明确,大多数研究表明结果无差异,但由于潜在混杂因素存在局限性。